Unknown

Dataset Information

0

Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.


ABSTRACT: SETTING:Anti-tuberculosis formulations necessitate uninterrupted treatment to cure tuberculosis (TB), but are characterised by suboptimal adherence, which jeopardises therapeutic efficacy. Long-acting injectable (LAI) formulations or implants could address these associated issues. OBJECTIVE:niazid, rifapentine, bedaquiline and delamanid-in adults for treatment for latent tuberculous infection (LTBI). DESIGN:PBPK models were developed and qualified against available clinical data by integrating drug physicochemical properties and in vitro and population pharmacokinetic data into a mechanistic description of drug distribution. Combinations of optimal dose and release rates were simulated such that plasma concentrations were maintained over the epidemiological cut-off or minimum inhibitory concentration for the dosing interval. RESULTS:The PBPK model identified 1500 mg of delamanid and 250 mg of rifapentine as sufficient doses for monthly intramuscular administration, if a formulation or device can deliver the required release kinetics of 0.001-0.0025 h-1 and 0.0015-0.0025 h-1, respectively. Bedaquiline and isoniazid would require weekly to biweekly intramuscular dosing. CONCLUSION:We identified the theoretical doses and release rates of LAI anti-tuberculosis formulations. Such a strategy could ease the problem of suboptimal adherence provided the associated technological complexities for LTBI treatment are addressed.

SUBMITTER: Rajoli RKR 

PROVIDER: S-EPMC6166436 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.

Rajoli R K R RKR   Podany A T AT   Moss D M DM   Swindells S S   Flexner C C   Owen A A   Siccardi M M  

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 20180801 8


<h4>Setting</h4>Anti-tuberculosis formulations necessitate uninterrupted treatment to cure tuberculosis (TB), but are characterised by suboptimal adherence, which jeopardises therapeutic efficacy. Long-acting injectable (LAI) formulations or implants could address these associated issues.<h4>Objective</h4>niazid, rifapentine, bedaquiline and delamanid-in adults for treatment for latent tuberculous infection (LTBI).<h4>Design</h4>PBPK models were developed and qualified against available clinical  ...[more]

Similar Datasets

| S-EPMC6917207 | biostudies-literature
| S-EPMC8957249 | biostudies-literature
| S-EPMC7263829 | biostudies-literature
| S-EPMC9926456 | biostudies-literature
| S-EPMC6182793 | biostudies-literature
| S-EPMC6891000 | biostudies-literature
| S-EPMC7249120 | biostudies-literature
| PRJEB4408 | ENA
| S-EPMC4368126 | biostudies-literature
| S-EPMC9911583 | biostudies-literature